Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).

Früh, Martin; Betticher, Daniel C; Stupp, Roger; Xyrafas, Alexandros; Peters, Solange; Ris, Hans Beat; Mirimanoff, Rene Olivier; Ochsenbein, Adrian F.; Schmid, Ralph; Matzinger, Oscar; Stahel, Rolf A; Weder, Walter; Guckenberger, Matthias; Rothschild, Sacha I; Lardinois, Didier; Mach, Nicholas; Mark, Michael; Gautschi, Oliver; Thierstein, Sandra; Biaggi Rudolf, Christine; ... (2019). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). Journal of thoracic oncology, 14(1), pp. 115-123. Elsevier 10.1016/j.jtho.2018.09.011

Text Früh SCHMID 19 JTO Multimodal Treatment in Operable Stage III NSCLC A Pooled Analysis on Long-Term Results of Three SAKK trials SAKK.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (581kB)

INTRODUCTION

Long-term data on outcomes of operable stage III NSCLC are scarce.

METHODS

Individual patient data from 368 patients enrolled in one phase III and two phase II trials were pooled and outcomes after applying the eighth (denoted with an asterisk [*]) versus the sixth TNM staging edition were compared. Patients were treated with either preoperative radiotherapy following 3 cycles of induction chemotherapy (trimodal) or neoadjuvant chemotherapy alone (bimodal).

RESULTS

With the sixth version, the 5- and 10-year survival rates were 38% and 28% for stage IIIA, respectively, and 36% and 24% for stage IIIB, respectively. Factors associated with improved 5-year overall survival were younger age, R0 resection, and pathologic complete remission (pCR) (p = 0.043, p < 0.001 and p = 0.009). With the eighth TNM staging version, 162 patients were moved from stage IIIA to IIIB*. The 5- and 10-year survival rates were 41% and 29% for stage IIIA*, respectively, and 35% and 27% for stage IIIB* patients, respectively. There was no difference in the bi- versus trimodal group with regard to median overall survival (28 months [95% confidence interval (CI): 21-39 months] and 37 months [95% CI: 24-51 months], p = 0.9) and event-free survival (12 months [95% CI: 9-15 months] versus 13 months [95% CI: 10-22 months], p = 0.71).

CONCLUSIONS

We showed favorable 10-year survival rates of 29% and 27% in stage IIIA* and IIIB*, respectively. Younger age, R0 resection, and pathologic complete response were associated with improved long-term survival. Outcomes using the sixth versus eighth edition of the TNM classification were similar in operable stage III NSCLC.

Interest & Impact

Downloads

1 since deposited on 12 Nov 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item